When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Hepatitis B

Evidence last reviewed: 19 Oct 2026
Topic last updated: 30 Oct 2026
30 Oct 2026

Bepirovirsen approval offers new option for treatment of chronic HBV infection

​The Food and Drug Administration (FDA) has approved a new first-of-its-kind treatment option for the management of chronic hepatitis B virus (HBV) infection. Bepirovirsen is a first-in-class, HBV mRNA-directed antisense oligonucleotide. The new treatment offers patients the possibility of maintaining viral suppression once chronic treatment has ended.

The FDA approval is for the treatment of chronic HBV infection in adults without cirrhosis. Specifically, it is indicated for patients who have been on nucleoside/nucleotide analog therapy for at least 6 months, and have suppressed HBV DNA and hepatitis B surface antigen (HBsAg) levels ≤3000 IU/mL (as determined by an FDA-authorized test).

Functional cure (sustained loss of HBsAg and undetectable HBV DNA) is rare with current antiviral treatments, and some people remain on treatment indefinitely. Bepirovirsen offers a better chance of functional cure after 6 months of treatment. Trials report a functional cure rate of 19% at week 72 in those who receive bepirovirsen for 24 weeks compared to 0% in those who received placebo. Response rates were higher (26%) in patients with a lower baseline HBsAg level ≤1000 IU/mL. Common adverse effects included injection-site reactions, fever, fatigue, headache, and a temporary rise in alanine aminotransferase levels.[161]

The treatment is administered as a subcutaneous injection for 6 months, and must be used in combination with oral nucleoside/nucleotide analog therapy. For convenience, it can be self-administered after the first dose.

Bepirovirsen has not yet been incorporated into established clinical practice recommendations, and its use should only be considered in the context of its emerging evidence base, which remains limited. The European Medicines Agency (EMA) has not approved it as yet, but it is currently under review.

Globally, there were 240 million people living with chronic HBV infection in 2024, representing 2.9% of the global population.

See Management: emerging

Original source of update

Summary

Definition

History and exam

Key diagnostic factors

  • high risk of exposure
Full details

Other diagnostic factors

  • asymptomatic
  • jaundice
  • hepatomegaly
  • ascites
  • fever/chills
  • malaise
  • maculopapular or urticarial rash
  • right upper quadrant pain
  • fatigue
  • nausea/vomiting
  • arthralgia/arthritis
  • anorexia
  • dark urine or clay-colored stool
  • palmar erythema
  • spider angiomata
  • splenomegaly
  • asterixis
Full details

Risk factors

  • perinatal exposure in an infant born to a hepatitis B virus (HBV)-infected mother
  • high-risk sexual behaviors
  • injection drug use
  • born in highly endemic region
  • family history of hepatitis B virus (HBV) infection, hepatocellular carcinoma (HCC), and/or chronic liver disease
  • household contact with hepatitis B virus (HBV) infection
  • history of incarceration
  • male sex
  • living with HIV
  • living with hepatitis C
  • blood or blood product transfusion
  • healthcare workers
  • hemodialysis
  • solid organ transplantation
Full details

Diagnostic tests

1st tests to order

  • hepatic panel
  • CBC
  • basic metabolic panel
  • coagulation profile
  • serum hepatitis B surface antigen (HBsAg)
  • serum antibody to hepatitis B surface antigen (anti-HBs)
  • serum antibody to hepatitis B core antigen (anti-HBc)
  • serum hepatitis B e antigen (HBeAg)
  • serum antibody to hepatitis B e antigen (anti-HBe)
  • serum quantitative hepatitis B virus (HBV) DNA
  • testing for coinfections
Full details

Tests to consider

  • abdominal ultrasound
  • vibration-controlled transient elastography (VCTE)
  • serum liver fibrosis biomarkers
  • aspartate aminotransferase-to-platelet ratio index (APRI)
  • liver biopsy
  • alpha-fetoprotein (AFP)
  • CT/MRI abdomen
  • drug resistance testing
  • hepatitis B virus (HBV) genotype
Full details

Treatment algorithm

ACUTE

acute HBV infection

ONGOING

chronic HBV infection and indication for treatment: nonpregnant adult without coinfection or cirrhosis or hepatocellular carcinoma

chronic HBV infection: nonpregnant adult with cirrhosis

chronic HBV infection: nonpregnant adult with hepatocellular carcinoma

chronic HBV infection: nonpregnant adult with HIV coinfection

chronic HBV infection: nonpregnant adult with hepatitis C coinfection

chronic HBV infection: nonpregnant adult with hepatitis D coinfection

chronic HBV infection: pregnant or breastfeeding

chronic HBV infection: children

Contributors

Authors

Jawad Ahmad, MD, FRCP, FAASLD

Professor of Medicine

Division of Liver Diseases

Mount Sinai Hospital

New York, NY

Disclosures

JA declares that he has no competing interests.

Acknowledgements

Dr Jawad Ahmad would like to gratefully acknowledge Dr Sateesh R. Prakash, Dr Siddarth Verma, Dr Smruti R. Mohanty, and Dr Jared Hossack, previous contributors to this topic.

Disclosures

SRP, SV, and JH declare that they have no competing interests. SRM serves as a speaker bureau for Bristol-Myers Squibb regarding the use of entecavir for the treatment of chronic hepatitis B.

Peer reviewers

George Y. Wu, MD, PhD

Chief

Hepatology Section

Department of Medicine

University of Connecticut Health Center

Farmington, CT

Disclosures

GYW is on the medical advisory boards of Gilead Sciences and Bristol-Myers Squibb.

Lucieni Oliveira Conterno, MD, PhD

Director

Clinical Epidemiology Unit

Marilia Medical School

Sao Paulo, Brazil

Disclosures

LOC declares that she has no competing interests.

Mamun-Al-Mahtab, MB BS, MSc, MD

Chairman

Bangladesh Primary Care Research Network

Dhaka, Bangladesh

Disclosures

MAM declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-99.Full text  Abstract

European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2025 Aug;83(2):502-83.Full text  Abstract

World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Mar 2024 [internet publication].​Full text

Ghany MG, Pan CQ, Lok AS, et al. AASLD ISDA practice guideline on treatment of chronic hepatitis B. Hepatology. 2026 Apr 1;83(4):974-97.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Differentials

    • Hepatitis A
    • Hepatitis C
    • Hepatitis D
    More Differentials
  • Guidelines

    • Clinical practice guidelines on the management of hepatitis B virus infection
    • Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection
    More Guidelines
  • Patient information

    Hepatitis B: should I have the vaccine?

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer